

# All Wales Medicines Strategy Group

## Annual Report 2022–2023

Supplement - accessible versions of graphs and tables

*“Supporting prudent prescribing to obtain the best  
outcomes from medicines for patients in Wales”*



This document is available in Welsh  
*Mae'r ddogfen hon ar gael yn Gymraeg*



# Delivering the recommendations of AWMSG's five-year strategy 2018–2023

AWMSG's medicines strategy for Wales for 2018–2023 identified four priority areas where AWMSG would focus its work.

1. Achieve health and wellbeing with the public, patients and professionals as equal partners through co-production.
2. Care for those with the greatest health need first, making the most effective use of all skills and resources.
3. Do only what is needed, no more, no less; and do no harm.
4. Reduce inappropriate variation using evidence-based practices consistently and transparently.


AWMSG set out recommendations for each area and identified outcomes to help successfully deliver its strategic goals. The table below gives an update on the recent work (April 2022 to March 2023) of AWMSG and its partners to implement the recommendations.

Task	Type	Strategy recommendation
<a href="#">Value-based prescribing – Strategy</a>	Strategy	3.6 Resource reallocation 4.3 Improving prescribing and medicines optimisation within NHS Wales
<a href="#">Value-based prescribing – Biological medicines for severe uncontrolled asthma</a>	Medicines optimisation resource	2.1 Workforce development 4.3 Improving prescribing and medicines optimisation within NHS Wales
<a href="#">Care home medicines optimisation toolkit</a>	Medicines optimisation resource	2.1 Workforce development 3.2 Medication review 3.4 Medicine-related harm 4.3 Improving prescribing and medicines optimisation within NHS Wales
<a href="#">Tramadol educational resources – Patient information leaflets</a>	Medicines optimisation resource	1.1 Partnership with the public 3.4 Medicine-related harm
<a href="#">All Wales guidance for prescribing intervals</a>	Medicines optimisation resource	2.1 Workforce development 4.3 Improving prescribing and medicines optimisation within NHS Wales
<a href="#">Resources for pharmacological management of pain</a>	Medicines optimisation resource	2.1 Workforce development 3.4 Medicine-related harm 4.3 Improving prescribing and medicines optimisation within NHS Wales
<a href="#">Maximising the opportunity presented by biosimilar medicines – A national strategy for Wales</a>	Strategy	3.6 Resource reallocation 4.3 Improving prescribing and medicines optimisation within NHS Wales

Task	Type	Strategy recommendation
<a href="#">Polypharmacy in older people: A guide for healthcare professionals</a>	Medicines optimisation resource	2.1 Workforce development 3.2 Medication review 3.4 Medicine-related harm 4.3 Improving prescribing and medicines optimisation within NHS Wales
<a href="#">National Prescribing Indicators (NPIs) 2022-2023: Quarterly reports</a>	Report	3.4 Medicine-related harm 4.3 Improving prescribing and medicines optimisation within NHS Wales 4.5 National Prescribing Indicators 4.8 Using data to improve patient outcomes
<a href="#">AWMSG Acknowledgement: Antibiotic Review Kit (ARK) Hospital Medication Record</a>	Medicines optimisation resource (Acknowledgement)	2.1 Workforce development 3.3 National prescribing and administration chart 3.4 Medicine-related harm 4.3 Improving prescribing and medicines optimisation within NHS Wales
<a href="#">NHS Wales inhaler carbon footprint reports</a>	Report	4.5 National Prescribing Indicators
<a href="#">AWMSG and the Well-being of Future Generations (Wales) Act</a>	Report	1.1 Partnership with the public 1.3 Ensuring fair and equitable provision of healthcare
<a href="#">Learning at Lunch: Rapid Therapeutic Updates</a>	Virtual training sessions	2.1 Workforce development
Updated process for reviewing orphan and ultra-orphan medicines and medicines developed specifically for rare diseases	Process update	4.6 Ensuring the appraisal process is reviewed and meets the developing needs of NHS Wales
Implementation of Equality and Health Impact Assessment (EqHIA) forms for AWMSG projects and policies	Process update	1.1 Partnership with the public 1.3 Ensuring fair and equitable provision of healthcare


<a href="#">Guide to collaborative working between NHS organisations, primary care contractors and pharmaceutical industry</a>	Resource	2.1 Workforce development 4.3 Improving prescribing and medicines optimisation within NHS Wales
<a href="#">Update to AWMSG recommendations review process including publication of new static list</a>	Process update	4.6 Ensuring the appraisal process is reviewed and meets the developing needs of NHS Wales
Review of the Free Medicines Supply process	Process update	1.3 Ensuring fair and equitable provision of healthcare 4.2 Nationally available medicines list

Figure 1. Prescribing in Wales of biosimilar medicines as a percentage of total prescribing ('reference' medicine plus biosimilar medicine) of six widely used biological medicines.




For five of the biological medicines shown, biosimilar medicines accounted for 80–100% of all prescriptions. A biosimilar version of ranibizumab only became available in May 2022. AWTTTC will monitor and report the use of new biosimilar medicines as they start to be prescribed in NHS Wales.

# Health Technology Assessment




### Type of submission for appraisal



\*Process introduced in 2021

\*\*Reassessment of emtricitabine/tenofovir disoproxil

### Appraisals with a Patient Access Scheme





# Membership

## AWMSG

Post	Member	Deputy
Chair	Prof Iolo Doull	Prof Dyfrig Hughes
Consultant in Public Health Medicine	Prof Stephen Monaghan	Awaiting nomination
Welsh Health Specialised Services Committee	Ms Eleri Schiavone	Dr Helen Fardy
Health Economist	Prof Dyfrig Hughes	Prof Deborah Fitzsimmons
ABPI (Wales)	Ms Kate Parrish Mr Tommy Price Mr Farhan Mughal	Attendance is rotated between the three named individuals
Lay representative	Mrs Pam James	Awaiting nomination
Lay representative	Ms Claire James	Mrs Julie Wilson-Thomas
Community Pharmacist	Mr Dylan Jones	Awaiting nomination
Medical Director	Dr Richard Skone	Dr Jim McGuigan
GP with prescribing lead role	Dr Jeremy Black	Awaiting nomination
Managed Sector Pharmacist	Ms Alison Hughes	Ms Rafia Jamil
Managed Sector Pharmacist	Mr Stuart Rees	Awaiting nomination
Director of Finance	Mr Hywel Pullen	Mr James Leaves
Senior Nurse	Mrs Mandy James	Mrs Katherine White
Other healthcare professions eligible to prescribe not already represented	Mrs Cathy Wynne	Mr Karl Jackson
Clinical Pharmacologist	Dr Alison Thomas	Dr Manjeet Singh
Hospital Consultant	Dr Samantha Cox	Dr Manjeet Singh

## AWPAG

Post and discipline	Member	Health board/ trust	Alternate
Chair, Consultant Clinical Pharmacologist	Dr Laurence Gray	Cardiff and Vale	Mrs Clare Clement
Doctor from each health board reflecting different roles			
General Practitioner	Dr Rebecca McGee (to Dec 22)	Aneurin Bevan	Dr David Pyle (Powys) (to Dec 22)
General Practitioner	Dr Gemma Rogers (from Jun 22)	Aneurin Bevan	
Hospital Consultant/General Practitioner	Nomination received	Betsi Cadwaladr	
Hospital Consultant	Dr Laurence Gray	Cardiff and Vale	
Hospital Consultant/General Practitioner	Awaiting nomination	Cwm Taf Morgannwg	
General Practitioner	Dr Richard Brown	Hywel Dda	
Hospital Consultant/General Practitioner	Awaiting nomination	Powys	
General Practitioner	Dr Phil Cox	Swansea Bay	
Hospital Consultant	Awaiting nomination	Velindre	
Pharmacist from each health board/trust reflecting different roles			
Pharmacist	Nomination received Mr Hywel Jones (to Dec 22)	Aneurin Bevan	Nomination received Ms Emily Knight (to Nov 22)
Pharmacist	Ms Vicky Allum (from Feb 23)	Betsi Cadwaladr	Awaiting nomination Mr Ben Woodhouse (to Jul 22)
Pharmacist	Mrs Clare Clement	Cardiff & Vale	Mr Emyr Stephens (from Nov 22)
Pharmacist	Mrs Helen Davies	Cwm Taf Morgannwg	Mrs Avril Tucker

## AWPAG

Prescribing Advisor	Mrs Hazel Hopkins	Hywel Dda	Mrs Sue Beach Ms Jenny Pugh-Jones (to Mar 23)
Chief Pharmacist	Mrs Jacqueline Seaton (from Nov 22)	Powys	Awaiting nomination Mr Adrian Byrne (to Dec 22)
Pharmacist	Mr Darren Smith	Swansea Bay	Nomination received
Chief Pharmacist	Mrs Bethan Tranter	Velindre	Mrs Sophie Harding
Community Pharmacist	Nomination received	All Wales	Awaiting nomination Sudhir Sehrawat (to Jun 22)
Medicines Safety Pharmacist			
	Dr Lynette James	All Wales	Awaiting nomination
Lay member			
	Mrs Fiona Woods (from Mar 23) Mr Malcolm Latham (from Mar 23) Mr David Barnard (to Jan 23) Mr Alan Meudell (to Jan 23)		Awaiting nomination
Healthcare professional eligible to prescribe			
	Mrs Amy Williams		Nomination received
Nurse			
	Mrs Sarah Davies		Awaiting nomination
Public Health Wales			
	Mrs Sian Evans (from Nov 22) Ms Rosemary Allgeier (to Nov 22)		Mrs Sian Evans (to Nov 22)

## AWPAG

Association of the British Pharmaceutical Industry Wales			
	Ms Sue Knights		Ms Rachel Jenkins
Non-voting members			
Director, Association of the British Pharmaceutical Industry Wales	Dr Rick Greville		Ms Joe Ferris
Director, British Generic Manufacturers Association	Mr Paul Fleming		Ms Carol Blount Mr Michael Clarke
Welsh Government	To be notified of representation before each meeting		
AWTTC Board Member and AWMSG Representative	To be notified of representation before each meeting		

## NMG

Post	Member	Deputy
Chair	Prof James Coulson	
Vice Chair	Dr Emma Mason	
Pharmacist 1	Mr Alan Clatworthy	Eleri Phillips
Pharmacist 2	Mrs Sue Beach	Mr Alun Kurmuually (from Jun 22)
Pharmacist 3	Mrs Teena Grenier	Awaiting nomination
Doctor 1 - Clinical Pharmacologist	Dr Emma Mason	Awaiting nomination
Doctor 2 - Hospital Consultant	Awaiting nomination	Awaiting nomination
Doctor 3 - General Practitioner	Awaiting nomination Dr Chalini Lankage (to Jul 22)	Dr Avkash Das Jain
Professions allied to medicine or eligible to prescribe	Mr Karl Jackson	Awaiting nomination
Public Health/Epidemiologist	Awaiting nomination	Awaiting nomination
Health Economist	Prof Deborah Fitzsimmons	Dr Catrin Plumpton
Association of the British Pharmaceutical Industry Member	Mr Sandeep Kiri Olga Ovcinnikova (from Nov 22) Dhwani Shah (from Feb 23) Mr Steven Lister (to Oct 22) Ms Holly Cranmer (to Oct 22)	Attendance is rotated between the three named individuals
Welsh Health Specialised Services Committee	Dr Andrew Champion	Dr Sian Lewis

## NMG

Lay Member	Mr William Anthony Esmond Mrs Fiona Woods (from Aug 22)	Mrs Pamela Jane James (from Aug 22)
Nurse	Mr Andrew Davies (from Jun 22) Mr Neil Thomas (to May 22)	Mrs Susan Newport



All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

Published by:

All Wales Therapeutics and Toxicology Centre  
The Routledge Academic Centre  
University Hospital Llandough  
Vale of Glamorgan  
CF64 2XX

On behalf of the All Wales Medicines Strategy Group

All enquiries should be directed to:

Mrs Ruth Lang  
Senior Liaison Manager  
Email: [awttc@wales.nhs.uk](mailto:awttc@wales.nhs.uk)  
Telephone: 029 218 26900

Please note information in this document is correct at the time of print but may be subject to change. For latest information, please visit [awttc.nhs.wales](http://awttc.nhs.wales) (English) and [cttcg.gig.cymru](http://cttcg.gig.cymru) (Welsh). English Twitter account [@AWTTComms](https://twitter.com/AWTTComms); Welsh Twitter account [@AWTTCymraeg](https://twitter.com/AWTTCymraeg).